← Eichor
Study identifier: NCT06774729 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

Development of a Radiomics Model With MR to Predict the Occurence of a Infiltration of Muscoskeletal Tumor

Condition: Soft Tissue Sarcoma (STS) · Bone Cancer Tumor  ·  Sponsor: IRCCS Azienda Ospedaliero-Universitaria di Bologna

PhaseN/A
Planned participants122
Who can joinAll sexes, 18 Years to no upper limit
Healthy volunteersNo

About this study

The goal of this observational study is to evaluate the feasibility and clinical utility of radiomics to diagnose peri-lesion tumour infiltration of tumours in participants with a suspect of Bone Cancer Tumor or Soft Tissue Sarcoma (STS). The main questions it aims to answer are: * is radiomics able to identify the ratio of participants truly diagnosed as positive to all those who had positive test results? * is radiomics able to identify the likelihood that a participant who has a negative test result indeed does not have the disease? Participants eligible for this study will get a MRI as part of their regular medical care. The only difference is that their data will be recorded and anonymously analyzed.

This description comes directly from the study's public registry record.

Talk to the study team

Vincenzo Lucidi, MD  ·  +39 3385246923  ·  vincenzo.lucidi@aosp.bo.it

Always discuss trial participation with your own doctor first.

Locations (1)

IRCCS Azienda Ospedaliero-Universitaria di BolognaBologna, ItalyRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06774729